List view / Grid view
Biomarkers aren’t just supporting drug discovery - they’re driving it. From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
Researchers have discovered that the protein intersectin plays a crucial role in organising synaptic vesicles – enabling direct communication essential for learning and memory.
Scientists at Washington University School of Medicine have discovered that mast cells – immune cells best known for triggering allergic reactions – also help protect the brain from bacterial and viral infections. This could have important implications for treating brain infections in the future.
Scientists have discovered that cancer cells generate an instant burst of energy when physically squeezed, helping them repair DNA damage and survive harsh environments. This discovery means that therapies targeting this new survival mechanism could be developed.
Recombinant antibody technology is redefining research standards - bringing biopharma-grade precision, consistency, and customisation to the lab. Discover how advances like Fc engineering and chimerisation are accelerating progress from basic discovery to clinical insight.
Scientists in Singapore have discovered that gut support cells – known as telocytes – use neuron-like extensions to deliver signals directly to intestinal stem cells. This could lead to new treatments for diseases such as inflammatory bowel disease and colon cancer.
As radioligand therapy continues to show promise, its application in solid tumours remains limited by long-standing biological challenges. In this interview, Julien Torgue, CSO at Orano Med, discusses a new collaborative platform – Radio-DARPins – and how it could help overcome key barriers to clinical progress.
Singapore researchers have found that cancer drug PRL3-zumab shows strong potential for treating wet age-related macular degeneration and diabetic retinopathy - two leading causes of blindness worldwide.
New therapeutic approaches are emerging for CNS disorders – but can they overcome the toughest barriers in drug development? Find out what is driving progress and what still stands in the way.
Scientists from Fudan University have halted the progression of ALSP, a rare and fatal brain disease, using a pioneering microglia replacement therapy - marking the first effective clinical approach to tackling the disease.
Scientists at Lund University have shown that aggressive melanoma tumours are driven by overactive mitochondrial processes – revealing a potential treatment strategy using drugs already approved for other conditions.
Single-cell and spatial technologies are giving researchers an unprecedented view of how brain diseases like Alzheimer’s really work. The result? Faster discovery, clearer targets and a new path towards more effective treatments.
Scientists from Nagoya University have developed a fast and safe method to create lung cells from skin-like fibroblasts - without using stem cells. This technique could allow for new regenerative therapies for diseases like chronic obstructive pulmonary disease (COPD).
Drug Target Review spoke with Giancarlo Basile at SLAS Europe 2025 about MGI’s bold shift from sequencing specialist to automation partner – helping research companies of all sizes achieve accuracy, speed and reproducibility.
Researchers at Tel Aviv University have developed a new mouse model that accurately mimics a rare and severe genetic disorder caused by mutations in the GRIN2D gene – allowing for study of the disease’s progression and the testing of potential drug therapies.
